PMID- 17643519
OWN - NLM
STAT- MEDLINE
DCOM- 20080904
LR  - 20181201
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 127
IP  - 2
DP  - 2008 Jul 4
TI  - Effects of levosimendan versus dobutamine on long-term survival of patients with 
      cardiogenic shock after primary coronary angioplasty.
PG  - 284-7
AB  - BACKGROUND: Cardiogenic shock (CS) after ST elevation myocardial infarction 
      (STEMI) worsens patient's outcome. Levosimendan treatment offers short-term 
      survival benefit in acute heart failure but its effect on long-term outcome 
      remains unclear. We sought to assess the effect on long-term survival of 
      levosimendan compared to dobutamine treatment in patients with STEMI 
      revascularized by primary coronary angioplasty (PCI) who subsequently developed 
      CS. METHODS AND RESULTS: Twenty-two consecutive STEMI patients with CS after PCI 
      randomized to receive levosimendan or dobutamine treatment for 24 h were 
      followed-up for twelve months. Complete follow-up was obtained in 100% of them. 
      The endpoint was cardiac death. Baseline clinical and haemodynamic 
      characteristics were similar in both groups. The probability of survival 
      calculated with Kaplan-Meier curves analysis showed no statistically significant 
      differences between both groups (p=0.24). CONCLUSIONS: Levosimendan compared to 
      dobutamine did not improve long-term survival in STEMI patients revascularized by 
      PCI who developed CS.
FAU - Samimi-Fard, Sima
AU  - Samimi-Fard S
FAU - Garcia-Gonzalez, Martin J
AU  - Garcia-Gonzalez MJ
FAU - Dominguez-Rodriguez, Alberto
AU  - Dominguez-Rodriguez A
FAU - Abreu-Gonzalez, Pedro
AU  - Abreu-Gonzalez P
LA  - eng
PT  - Letter
PT  - Randomized Controlled Trial
DEP - 20070723
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 349552KRHK (Simendan)
RN  - 3S12J47372 (Dobutamine)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Cardiotonic Agents/*therapeutic use
MH  - Dobutamine/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hydrazones/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*complications/*therapy
MH  - Proportional Hazards Models
MH  - Pyridazines/*therapeutic use
MH  - Shock, Cardiogenic/*drug therapy/etiology
MH  - Simendan
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/complications
EDAT- 2007/07/24 09:00
MHDA- 2008/09/05 09:00
CRDT- 2007/07/24 09:00
PHST- 2007/02/09 00:00 [received]
PHST- 2007/04/25 00:00 [accepted]
PHST- 2007/07/24 09:00 [pubmed]
PHST- 2008/09/05 09:00 [medline]
PHST- 2007/07/24 09:00 [entrez]
AID - S0167-5273(07)01198-9 [pii]
AID - 10.1016/j.ijcard.2007.04.143 [doi]
PST - ppublish
SO  - Int J Cardiol. 2008 Jul 4;127(2):284-7. doi: 10.1016/j.ijcard.2007.04.143. Epub 
      2007 Jul 23.